Key result
Following alcohol septal ablation for HOCM, patients with basal IVS thickness ≥30 mm had higher long-term all-cause mortality than those with <30 mm.
Why the study?
Guidelines suggest alcohol septal ablation is less effective in HOCM patients with severe left ventricular hypertrophy, but systematic data supporting this statement are lacking.
Does alcohol septal ablation have similar efficacy and safety in HOCM patients with severe septal hypertrophy (IVS ≥30 mm) compared to those with IVS <30 mm?
Cohort (n=1,519)
Yes
Does alcohol septal ablation have similar efficacy and safety in HOCM patients with severe septal hypertrophy (IVS ≥30 mm) compared to those with IVS <30 mm?
Alcohol septal ablation provides similar symptomatic relief and LVOT gradient reduction in HOCM patients with IVS ≥30 mm compared to those with IVS <30 mm, challenging current guidelines, though long-term mortality is slightly higher.
Answers are grounded in this paper and cite their sources.
ASA yields similar symptom relief and gradient reduction in severe septal hypertrophy; leaves open questions on excess mortality and guideline thresholds.
OBJECTIVE: The current guidelines suggest alcohol septal ablation (ASA) is less effective in hypertrophic obstructive cardiomyopathy (HOCM) patients with severe left ventricular hypertrophy, despite acknowledging that systematic data are lacking. Therefore, we analysed patients in the Euro-ASA registry to test this statement. METHODS: We compared the short-term and long-term outcomes of patients with basal interventricular septum (IVS) thickness <30 mm Hg to those with ≥30 mm Hg treated using ASA in nine European centres. RESULTS: A total of 1519 patients (57±14 years, 49% women) with symptomatic HOCM were treated, including 67 (4.4%) patients with IVS thickness ≥30 mm. The occurrence of short-term major adverse events were similar in both groups. The mean follow-up was 5.4±4.3 years and 5.1±4.1 years, and the all-cause mortality rate was 2.57 and 2.94 deaths per 100 person-years of follow-up in the IVS <30 mm group and the IVS ≥30 mm group (p=0.047), respectively. There were no differences in dyspnoea (New York Heart Association class III/IV 12% vs 16%), residual left ventricular outflow tract gradient (16±20 vs 16±16 mm Hg) and repeated septal reduction procedures (12% vs 18%) in the IVS <30 mm group and IVS ≥30 mm group, respectively (p=NS for all). CONCLUSIONS: The short-term results and the long-term relief of dyspnoea, residual left ventricular outflow obstruction and occurrence of repeated septal reduction procedures in patients with basal IVS ≥30 mm is similar to those with IVS <30mm. However, long-term all-cause and cardiac mortality rates are worse in the ≥30 mm group.
No takes yet. Share an insight, caveat, or question.
Veselka et al. (2019) conducted a cohort in Hypertrophic obstructive cardiomyopathy (HOCM) (n=1,519). Basal interventricular septum (IVS) thickness ≥30 mm vs. Basal interventricular septum (IVS) thickness <30 mm was evaluated on All-cause mortality rate (deaths per 100 person-years) (p=0.047). Following alcohol septal ablation for HOCM, patients with basal IVS thickness ≥30 mm had higher long-term all-cause mortality than those with <30 mm.
Synapse has enriched 10 related papers. Consider them for comparative context: